Conduit Pharmaceuticals (CDT) said Wednesday it has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, citing a notification from the stock exchange.
The biopharmaceutical company said Nasdaq's hearing panel has implemented a one-year Discretionary Panel Monitor starting May 15 to ensure long-term compliance.
Shares of the company were more than 3% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.